Search Results 5961-5970 of 25294 for oral

  1. A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) - Mayo Clinic

    Able to swallow oral medication. Key Exclusion Criteria: 1. Patients with uveal or mucosal melanoma 2. Prior therapy with an ERK-, MEK-, RAF-, or RAS ...

  2. Non Clinical Trials

    After 6 cycles, maintenance rituximab may be administered per physician discretion. Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell ...

  3. Bladder cancer - Doctors and departments - Mayo Clinic

    ... Oral and throat cancer, Laryngeal cancer, Salivary gland cancer, Oropharyngeal cancer, Hypopharyngeal cancer. Show more areas of focus for Homan Mohammadi ...

  4. Publications - Matt P. Thorpe, M.D., Ph.D. - Mayo Clinic

    Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis. Inflamm Bowel Dis. 2013 Feb; 19 (2):301 ...

  5. YA-101 in Subjects with Multiple System Atrophy - Mayo Clinic

    Able to swallow oral suspension drugs. Able to ambulate without the assistance of another person, defined as ability to walk at least 10 meters. Use of ...

  6. Tongue cancer - Doctors and departments - Mayo Clinic

    Investigating tumor growth factors for oral cancer. Evaluating new methods of use for chemotherapy. Evaluating new radiation therapy regimens. Investigating ...

  7. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) - Mayo Clinic

    WOCBP taking oral contraceptives (OCs) also have to use one barrier method. Exclusion Criteria: 1. Prebronchodilator Forced Expiratory Volume in 1 second ...

  8. Diabetic nephropathy (kidney disease) - Doctors and departments - Mayo Clinic

    Research at Mayo Clinic in diabetic nephropathy includes developing new diagnostic and treatment tools, such as oral medicines that may help stop or delay ...

  9. An Extension Study Monitoring the Safety of Patients with Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 - Mayo Clinic

    ... oral contraceptive pill or transdermal patch, spermicide and barrier [condoms], intrauterine device, implants for contraception, injections for ...

  10. Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid - Mayo Clinic

    The primary objective of the study is to compare the effect of daily oral administration of elafibranor 80mg and 120 mg on change in serum alkaline ...